A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Identifieur interne : 001D94 ( Ncbi/Merge ); précédent : 001D93; suivant : 001D95A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
Auteurs : O. Rascol [France] ; A J Lees ; J M Senard ; Z. Pirtosek ; C. Brefel ; J L Montastruc ; D. FuellSource :
- Advances in neurology [ 0091-3952 ] ; 1996.
English descriptors
- KwdEn :
- Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Drug Therapy, Combination, Humans, Indoles (administration & dosage), Indoles (adverse effects), Indoles (therapeutic use), Levodopa (therapeutic use), Movement Disorders (drug therapy), Movement Disorders (physiopathology), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Receptors, Dopamine D2 (agonists).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agonists, Indoles.
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Indoles.
- chemical , agonists : Receptors, Dopamine D2.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Indoles, Levodopa.
- drug therapy : Movement Disorders, Parkinson Disease.
- physiopathology : Movement Disorders, Parkinson Disease.
- Drug Therapy, Combination, Humans.
PubMed: 8615176
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001598
- to stream PubMed, to step Curation: 001557
- to stream PubMed, to step Checkpoint: 001557
Links to Exploration step
pubmed:8615176Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Pirtosek, Z" sort="Pirtosek, Z" uniqKey="Pirtosek Z" first="Z" last="Pirtosek">Z. Pirtosek</name></author><author><name sortKey="Brefel, C" sort="Brefel, C" uniqKey="Brefel C" first="C" last="Brefel">C. Brefel</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Fuell, D" sort="Fuell, D" uniqKey="Fuell D" first="D" last="Fuell">D. Fuell</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1996">1996</date><idno type="RBID">pubmed:8615176</idno><idno type="pmid">8615176</idno><idno type="wicri:Area/PubMed/Corpus">001598</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001598</idno><idno type="wicri:Area/PubMed/Curation">001557</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001557</idno><idno type="wicri:Area/PubMed/Checkpoint">001557</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001557</idno><idno type="wicri:Area/Ncbi/Merge">001D94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Pirtosek, Z" sort="Pirtosek, Z" uniqKey="Pirtosek Z" first="Z" last="Pirtosek">Z. Pirtosek</name></author><author><name sortKey="Brefel, C" sort="Brefel, C" uniqKey="Brefel C" first="C" last="Brefel">C. Brefel</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Fuell, D" sort="Fuell, D" uniqKey="Fuell D" first="D" last="Fuell">D. Fuell</name></author></analytic><series><title level="j">Advances in neurology</title><idno type="ISSN">0091-3952</idno><imprint><date when="1996" type="published">1996</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Indoles (administration & dosage)</term><term>Indoles (adverse effects)</term><term>Indoles (therapeutic use)</term><term>Levodopa (therapeutic use)</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (physiopathology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Receptors, Dopamine D2 (agonists)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Indoles</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8615176</PMID><DateCreated><Year>1996</Year><Month>05</Month><Day>31</Day></DateCreated><DateCompleted><Year>1996</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0091-3952</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><PubDate><Year>1996</Year></PubDate></JournalIssue><Title>Advances in neurology</Title><ISOAbbreviation>Adv Neurol</ISOAbbreviation></Journal><ArticleTitle>A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.</ArticleTitle><Pagination><MedlinePgn>531-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Senard</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Pirtosek</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Brefel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Fuell</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Neurol</MedlineTA><NlmUniqueID>0367524</NlmUniqueID><ISSNLinking>0091-3952</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>030PYR8953</RegistryNumber><NameOfSubstance UI="C046649">ropinirole</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8615176</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Brefel, C" sort="Brefel, C" uniqKey="Brefel C" first="C" last="Brefel">C. Brefel</name><name sortKey="Fuell, D" sort="Fuell, D" uniqKey="Fuell D" first="D" last="Fuell">D. Fuell</name><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name><name sortKey="Pirtosek, Z" sort="Pirtosek, Z" uniqKey="Pirtosek Z" first="Z" last="Pirtosek">Z. Pirtosek</name><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001D94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:8615176
|texte= A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8615176" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |